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Abstract 
Objective: 
A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity. 
The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in 
children with PDD and hyperactivity. 
Methods: 
Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent 
history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a 
multisite, placebo-controlled trial. 
Results: 
Children (23 boys and 2 girls) with a mean age of 9.03 (±3.14) years entered the open-label trial. 
After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist 
(ABC) went from a mean of 31.3 (±8.89) at baseline to 18.9 (±10.37) (effect size = 1.4; p < 0.001). The 
teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (±9.12) at baseline to 22.3 (±9.44) 
(effect size = 0.83; p < 0.01). Twelve children (48%) were rated as Much Improved or Very Much 
Improved on the Clinical Global Impressions– Improvement. Doses ranged from 1.0 to 3.0 mg/day in two 
or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia 
or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no 
significant changes in pulse, blood pressure, or electrocardiogram. 
Conclusions: 
Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-
controlled studies are needed to guide clinical practice. 
Introduction 
Pervasive Developmental Disorders (PDDs), such as autistic disorder, Asperger’s 
disorder, and PDD-not otherwise specified (NOS), are chronic conditions of early childhood 
onset defined by varying degrees of social impairment, delayed and deviant language, and 
repetitive behavior (Diagnostic and Statistical Manual of Disorders, 4th edition, Text Revision; 
DSM-IV-TR; American Psychiatric Association, 2000). The PDDs are often accompanied by 
motor restlessness, overactivity, distractibility, and disruptive behavior (Lecavalier et al., in 
press). For some children with PDD, these symptoms may be severe enough to warrant 
pharmacotherapy. Indeed, expert clinicians and researchers ranked the stimulants and α2-
adrenergic agonists as the two most appropriate medication groups for treating children with 
developmental disabilities and hyperactivity (Rush and Francis 2000). Despite the opinion of 
these experts, however, the empirical support for the use of these medications in PDD is limited. 
The stimulants are first-line treatments for typically developing children with inattention, 
hyperactivity, and impulsiveness. Of the currently available stimulants, methylphenidate is the 
most commonly used. Data from the Multimodal Treatment Study of ADHD (MTA) indicate 
that 75% of typically developing children with attention-deficit/hyperactivity disorder (ADHD) 
benefit from methylphenidate during both short- and long-term treatment (MTA Cooperative 
Group 1999; Greenhill et al. 2001). To date, only a handful of stimulant trials in children with 
PDD and hyperactivity have been undertaken (Aman et al. 2003). The Research Units on 
Pediatric Psychopathology (RUPP) Autism Network recently completed a multisite trial in 
children with PDD accompanied by hyperactivity and showed that methylphenidate was superior 
to placebo (RUPP Autism Network 2005). Compared to typically developing children with 
ADHD, however, the magnitude of response to methylphenidate was modest and there was a 
relatively high frequency of adverse events leading to discontinuation. When stimulants are not 
successful in reducing the primary symptoms of ADHD, clinicians turn to nonstimulant 
medications such as clonidine, guanfacine, atomoxetine, or desipramine (Scahill et al. 2001; 
Spencer et al. 2001; TS Study Group 2001; Michelson et al. 2002). Although each of these 
compounds has been evaluated in one or more placebo-controlled trials in typically developing 
children with ADHD, none of these nonstimulant medications has been well studied in children 
with PDD and hyperactivity. 
The α2 agonist clonidine has been used in the treatment of overactivity and impulsiveness 
in children for over 2 decades (Leckman et al. 1991; TS Study Group 2001). The chief drawback 
of clonidine is sedation (Jaselkis et al. 1992; TS Study Group 2001). Guanfacine is a newer α2 
adrenergic agonist that appears to be less sedating than clonidine and, therefore, may be better 
tolerated. The plasma half-life of guanfacine in healthy adults is 10–30 hours compared with 4–
10 hours for clonidine. This longer duration of action may promote better compliance due to the 
need for less frequent dosing and may protect against the rebound effects associated with abrupt 
discontinuation of clonidine (Leckman et al. 1986). In addition, animal studies show that 
guanfacine improves prefrontal cortical function in nonhuman primates, without sedation further 
supporting differentiation of these pharmacological effects (Avery et al. 2000). The only two 
published placebo-controlled trials of guanfacine in pediatric populations provide somewhat 
inconsistent results. Scahill et al. (2001) showed that guanfacine was superior to placebo on 
teacher-rated ADHD measures in children with tic disorders and ADHD. The medication was 
also helpful in reducing tics. Cummings et al. (2002) reported no benefit over placebo in children 
with Tourette syndrome. However, this trial involved a small sample and did not specifically 
target ADHD symptoms. To date, there is only a retrospective report of guanfacine in 
developmentally disabled children. This report showed a modest benefit for guanfacine, 
although, once again, target symptoms were not clearly specified (Posey et al. 2004). The 
purpose of the present study is to collect prospective pilot data on the safety and effectiveness of 
guanfacine in the treatment of children with PDD and hyperactivity. 
Methods 
Design 
This was a multisite, 8-week, prospective, open-label trial of guanfacine in children with 
PDD and high levels of hyperactivity and distractibility. The trial was designed as companion 
study to a mulitsite, placebo-controlled trial of methylphenidate in children with PDD and 
hyperactivity conducted by the RUPP Autism Network (2005). Subjects entered the guanfacine 
study by one of two pathways: (1) If there was a recent history of failed treatment with 
methylphenidate and all other entry criteria for the RUPP methylphenidate study were met; (2) if 
the child did not improve on methylphenidate in the RUPP multisite study. Eligible subjects 
were boys and girls between the ages of 5 and 14 years; DSM-IV diagnosis of PDD (PDD-NOS, 
Asperger’s disorder, autistic disorder) based on a DSM-IV clinical diagnosis and corroborated by 
the Autism Diagnostic Interview-Revised (Lord et al. 1997) accompanied by clinically 
significant symptoms of ADHD (i.e., impulsiveness and hyperactivity) as evidenced by a score 
of at least Moderate (≥ 4) on the Clinical Global Impressions (CGI) Severity score for ADHD 
symptoms. Subjects also had to have an average score of 1.7 on the parent-rated or teacher-rated 
hyperactive-impulsive items of the SNAP-IV (Swanson et al. 2001; http://adhd. net). (This 
SNAP threshold is approximately 1.2 SD above the mean for typically developing children 
(Swanson et al. 2001). This relatively low threshold was set because some items on the SNAP 
imply use of language and often do not apply to children with PDD. (Indeed, these items were 
consistently left blank by some parents and teachers.) Other entry criteria required a mental age 
of at least 18 months as measured by any one of the following tests: the Slosson Intelligence 
Test, the Wechsler Intelligence Scale for Children (when possible), or by the Revised Leiter 
International Intelligence Test or the Mullen Scales of Early Development (Slosson 1983; 
Wechsler 1991; Mullen 1995; Roid and Miller 1997). 
Procedures 
Following a detailed screening that included medical, psychiatric, and developmental 
assessments, eligible children were enrolled via one of the pathways mentioned above. Subjects 
were seen weekly for the first 4 weeks to evaluate response and tolerability and then seen every 
other week until week 8. Visits included vital signs, height and weight, and a systematic review 
of adverse events. Efficacy ratings were collected at baseline and every 4 weeks. 
Measures: 
The primary outcome measures were the parent-rated Hyperactivity subscale of the 
Aberrant Behavior Checklist (ABC) and the Improvement item of the CGI scale (CGI-I). The 
Hyperactivity subscale of the ABC contains 16 items that reflect hyperactivity and impulsive 
behavior (Aman et al. 1985) and was designed to measure change in treatment studies and has 
been normed in developmentally disabled populations (Marshburn et al. 1992; Brown et al. 
2002). Higher scores reflect greater symptom severity. The ABC also contains several other 
subscales on the basis of factor analysis including: Irritability, Social Withdrawal, Stereotypy, 
and Inappropriate Speech. These scales have also been used to measure change in clinical trials 
for children with autism (RUPP Autism Network 2002). 
The CGI-I is a commonly used 7-point scale designed to reflect overall change (Guy 
1976). In this study, a research clinician trained to reliability used all available information to 
judge whether there was any change from baseline. If so, the change was rated as positive 
(Minimally Improved, Much Improved, Very Much Improved) or negative (Minimally Worse, 
Much Worse, or Very Much Worse). Ratings of Much Improved or Very Much Improved were 
used to define a positive clinical response with all other responses used to define inadequate 
response. 
Other important outcomes included the teacher-rated Hyperactivity subscale of the ABC 
and the parent- and teacher-rated SNAP-IV. The SNAP-IV is an 18-item scale based on the 
DSM-IV symptoms of ADHD (Swanson et al. 2001). It has been used as a measure of change in 
clinical trials in typically developing children with ADHD (MTA Group 1999), but less 
commonly in children with PDD. 
Medication 
The medication regimen was determined by body weight. Children below 25 kg started 
with 0.25 mg at bedtime and increased to 0.25 mg bid on day 4. Thereafter, dosage increases 
were made in 0.25-mg increments, approximately every fourth day as tolerated, to a maximum of 
3.5 mg per day, given on a tid schedule (e.g., 8 am, 2 pm, and 8 pm). For children ≥ 25 kg, the 
guanfacine dose schedule was similar, but starting with 0.5 mg at night and increases in 0.5 mg 
increments. The maximum dose for these children was 5.0 mg/day on a tid schedule. There were 
no planned dose increases after week 5. Medication decreases to manage adverse effects were 
permitted at any time. 
Results 
Twenty seven subjects met eligibility criteria at baseline. However, 2 subjects, who did 
not improve on methylphenidate in the multisite trial, declined further study treatment. Thus, 25 
subjects (mean age = 9.03 ± 3.14) entered the open-label trial. Of these, 14 entered directly due 
to recently failed treatment with methylphenidate; the other 11 did not show improvement with 
methylphenidate during the multisite trial. The sample included 92% boys (n = 23); 72% (n = 18) 
were Caucasian, 24% (n = 6) were African-American, and 4% (n = 1) were Hispanic. Table 1 
presents demographic and clinical characteristics of the study sample. 
Characteristic n (%) 
Boys 23 (92) 
Caucasian 18 (72) 
Black 6 (24) 
Hispanic 1 (4) 
Diagnosis  
Autistic disorder 7 (28) 
PDD-NOS 18 (72) 
 Mean (SD) 
Age 9.0 ± 3.14 
IQ 50.9 (31.56) 
Vineland  
COM 54.7 ± 27.0 
DLS 42.9 ± 20.9 
SD 51.9 ± 15.2 
PDD = Pervasive developmental disorder; NOS = not otherwise specified; SD = standard deviation; COM 
= Communication; DLS = Daily Living Skills. 
Table 1. Baseline Clinical Characteristics of Children with PDD in Guanfacine Trial 
On the basis of data from Brown et al. (2002), the population mean on the ABC 
Hyperactivity subscale for developmentally disabled children receiving developmental 
disabilities services in the age group of this trial was 12.92 ± 11.70. As shown in Table 2, the 
mean score of 31.2 ± 8.77 on the parent-rated ABC Hyperactivity subscale in this sample was 
nearly 2 SD above the population mean (Brown et al. 2002). Tables 2 and Table 3 show the 
results on the parent- and teacher-rated ABC subscales, respectively. The parent-rated 
Hyperactivity declined 40% from 31.2 at baseline to 18.9 at the endpoint. This endpoint score is 
below 1 SD above the normative value and equals a pre- and post-treatment effect size of 1.4 
(mean change from baseline to endpoint divided by the SD at baseline). Similarly, the teacher-
rated Hyperactivity subscale declined 25% from 29.9 at baseline to 21.9 at endpoint for an effect 
size of 0.83. As shown in Table 2, parents rated significant reductions on the Irritability, 
Stereotypic Behavior, and Social Withdrawal subscales. By contrast, although teacher ratings 
were similar to parent ratings in severity at baseline, teachers reported modest improvements on 
these same measures at the endpoint. 
Subscale Baseline (SD) Endpoint (SD) Change score % change t-test p value 
Hyperactivity 31.2 (8.77) 18.9 (10.37) 12.3 39% 5.4 <0.001 
Irritability 17.4 (13.17) 11.5 (8.28) 5.9 34% 2.75 0.01a 
Social withdrawal 12.7(10.06) 7.6 (5.69) 5.1 40% 3.05 <0.01a 
Stereotypy 8.8 (5.76) 5.4 (4.83) 3.4 39% 3.28 <0.01a 
Inappropriate speech 5.0 (4.40) 4.3 (5.14) 0.7 14% 0.64 0.53 
SD = Standard deviation. 
ap < 0.05 after correction for multiple comparisons. 
Table 2.  Parent-Rated Aberrant Behavior Checklist Subscale Scores Pre- and Post-Treatment 
Subscale Baseline (SD) Endpoint (SD) Change score % Change t-test p value 
Hyperactivity 29.9(10.09) 21.9 (9.56) 8.0 27% 3.4 <0.01 
Irritability 16.8 (10.57) 14.4 (8.92) 2.4 14% 1.48 0.15 
Social withdrawal 13.0 (12.20) 11.8 (10.38) 1.2 9.2% 0.92 0.37 
Stereotypy 7.5 (5.35) 6.6 (5.48) 0.9 12% 1.12 0.27 
Inappropriate speech 5.1 (4.36) 6.0 (4.34) -0.9 -18% 1.13 0.27 
SD = Standard deviation. 
Table 3. Teacher-Rated Aberrant Behavior Checklist Subscale Scores at Pre- and Post-Treatment 
Table 4 shows parent- and teacher-rated change on the SNAP-IV scale. There is good 
agreement between parents and teachers on all SNAP-IV scales, although the magnitude of 
change was greater on parent ratings. Using all available data, the clinician rated 12 of 25 (48%) 
children as Much Improved or Very Much Improved at week 8. Two subjects withdrew due to 
lack of efficacy. 
In doses ranging from 1.0 mg/day to 3.0 mg/day in two or three divided doses, 
guanfacine was well tolerated. There were no serious adverse effects. Common adverse events 
included sedation (n = 10), irritability (n = 7), sleep disturbance (e.g., insomnia or midsleep 
awakening) (n = 6), increased aggression or self-injury (n = 4), decreased appetite (n = 4), 
constipation (n = 3), perceptual disturbance (n = 2) (defined as visual distortion of size and 
distance), and agitation (n = 1). Several of these adverse effects occurred in the same subjects. 
Three subjects withdrew prematurely due to irritability (being moody, tearful, and easily 
frustrated) (see Table 5). Systolic blood pressure showed a mean decline of about 7 points at 4 
weeks, but returned to baseline by week 8 (see Fig. 1). Diastolic blood pressure remained stable 
throughout the 8-week trial (see Fig. 2). There were no clinically significant changes in the 
electrocardiogram taken at week 8 compared to the endpoint, as determined by a pediatric 
cardiologist at each site. 
Discussion 
This prospective, open-label trial in children with PDD accompanied by hyperactivity 
and impulsive behavior showed that guanfacine was associated with a 39% improvement over 
Subscale Baseline (SD) Endpoint (SD) Change score % change t-test p value 
Parent       
Total 35.5 (8.21) 22.7 (10.02) 12.8 36% 5.98 <0.0001 
Inattention 18.2 (5.05) 12.4 (5.56) 5.8 32% 4.90 <0.0001 
Hyperactivity 17.3 (4.44) 10.2 (5.40) 7.1 41% 6.27 <0.0001 
Teacher       
Total 33.1 (10.43) 27.2 (10.44) 5.9 18% 2.71 0.01 
Inattention 16.9 (6.76) 14.2 (5.97) 2.7 16% 2.46 0.02 
Hyperactiviry 16.2 (5.30) 13.0 (5.85) 3.2 20% 2.67 0.01 
SD = Standard deviation. 
Table 4. Parent and Teacher Snap-IV Scores at Baseline and 8 Weeks 
Adverse eventa n (%) Study termination 
Sedation 7 (28)  
Irritability 7 (28) 3 
(moody, tearful, easily frustrated)   
Sleep disturbance 6 (24)  
(insomnia or mid-sleep awakening)   
Aggression or self-injury 4 (16)  
Tiredness 3 (12)  
Decreased appetite 2 (8)  
Constipation 2 (8)  
Talkativeness 1 (4)  
Perceptual disturbance 2 (8) 1 (with agitation) 
(altered sense of size and distance)   
aSeveral subjects experienced more than one adverse event. 
Table 5. Probable Drug-related Adverse Event Reported by Parents During 8-Week Study 
baseline on the parent-rated ABC Hyperactivity subscale and SNAP-IV scales. This 12-point 
improvement on the parent-rated ABC Hyperactivity subscale was virtually identical to the 
magnitude of change observed in the placebo-controlled trial of risperidone in children with 
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FIG. 2. Diastolic blood pressure for entire sample across 8 weeks of guanfacine trial. 
Guanfacine was also associated with improvements on teacher ratings, although of lesser 
magnitude than parent ratings. This pattern of response by the informant was remarkably similar 
to the results in the RUPP Autism Network methylphenidate study (RUPP Autism Network, in 
press). One possible explanation for the lower magnitude of response by teachers in these studies 
of children with PDD and hyperactivity is the variability of classroom placements in this 
population. Children in special education classrooms with high teacher-to-student ratios may 
have greater structure and different standards for acceptable behavior. By contrast, the abnormal 
behavior of children with PDD in mainstream classes may be more noticeable and elicit different 
responses on rating scales from regular classroom teachers. This study was not large enough to 
examine teacher rating according to classroom type. 
Although gains were largest in the domains of hyperactivity and impulsiveness, gains 
were also observed on parent ratings of irritable and explosive behavior, stereotypies, and social 
interaction. The improvements in explosive behavior and stereotypies is not surprising given that 
a prior study in children with tic disorders showed improvements in impulsive behavior and tics 
(Scahill et al. 2001). The improvement on the parent-rated Social Withdrawal scale, which 
partially reflects interest in others and positive response to interaction from others, is not easily 
explained. If replicated by other studies, the observed improvement in social interaction may be 
the natural consequence of decreased involvement in stereotypic behavior. However, these 
ancillary benefits reflected in parent ratings are tempered by the fact that the teacher ratings did 
not show similar benefits. The Social Withdrawal also contains items that describe a lack of 
energy. Given that sedation was a noticeable adverse effect in this study, it is interesting to note 
that “lack of energy” did not seem to influence parental perceptions of social behavior on this 
scale. 
Sedation, sleep disturbance, and irritability were adverse effects that required dose 
reduction, dose adjustment, or discontinuation in some cases. Effects on blood pressure and pulse 
were modest and appeared to diminish over time. To manage sleep disturbance, research 
clinicians redistributed the doses by giving higher doses prior to bedtime or by changing the time 
of the bedtime dose (generally moving it closer to actual bedtime). Increased irritability, which 
occurred in 7 subjects, appeared to be dose related because dose reduction resulted in resolution 
in 3 cases, was self-limited in 1 case, and led to discontinuation in 3 cases. Parents described this 
irritability as “grouchy,” “easily frustrated—even tearful,” although not typically explosive. This 
adverse event was not reported in the either of the controlled studies in children with tic 
disorders (Scahill et al. 2001; Cummings et al. 2002), suggesting that children with PDD may be 
more vulnerable to this effect. 
The results of this study are generally consistent with the findings by Scahill et al. (2001) 
and more encouraging than the retrospective report of 80 children with PDD (Posey et al. 2004). 
In that report, guanfacine was judged to be effective in 23% (19 of 80) subjects as measured by a 
score of Much Improved or Very Much Improved on the CGI-I. Comparison of our current 
results with the findings from Posey et al. (2004) is hampered by the retrospective nature of that 
report and the less specific target symptoms for the medication in that case series. 
Guanfacine is an α2 adrenergic agonist that shares some pharmacological features with 
clonidine (Newcorn et al. 2003). Clonidine was presumed to enhance prefrontal function 
indirectly by decreasing the firing of presynaptic noradrenergic receptors in the locus coeruleus 
(LC). This reduced firing by LC neurons exerts a regulatory effect on norepinephrine function 
and decreases arousal. Animal and human studies over the past 2 decades, however, have shown 
that guanfacine can have direct effects on prefrontal function via postsynaptic effects in 
prefrontal regions (Arnsten and Li 2004). This action may contribute to direct enhancement of 
prefrontal function, resulting in decreased distractibility, impulsiveness, and overactivity 
(Arnsten and Li 2004). Although the results of this pilot study cannot directly confirm this 
mechanism, these results do suggest that guanfacine may be a useful alternative for the treatment 
of hyperactivity in children with PDD. Large-scale, placebo-controlled studies are needed to 
guide clinical practice. 
The findings of this study need to be interpreted with due consideration of the limitations. 
First, this was a small study comprised of children with PDD who were nonresponders to 
methylphenidate. Whether these generally positive results would be observed in a similar sample 
of children with PDD but no prior history of stimulant failure is not clear and warrants further 
study. Simply stated, the findings of this pilot trial may only be relevant to patients who have 
shown an inadequate response to stimulant treatment. Second, there was no placebo control. The 
absence of a placebo control makes it difficult to be certain that the observed improvements are 
attributable to the study medication or to nonspecific factors, such as the clinical attention that 
comes with study participation or the passage of time. In the absence of placebo control, it is not 
possible to adjust the study results for these nonspecific factors. Finally, the trial was relatively 
short term. Thus, we can not make any statements about the long-term effectiveness or 
tolerability of guanfacine in this population. 
In conclusion, the results of this study suggest that guanfacine may be a useful treatment 
for hyperactivity in children with PDD who do not show improvement with methylphenidate. In 
this clinical population, guanfacine appears to better tolerated than clonidine (Jaselkis et al. 
1992). Guanfacine should be started at low doses and increased gradually to avoid adverse 
effects, particularly sedation. Although modest, effects on blood pressure appear to be most 
evident early in treatment during the dose-adjustment phase. Therefore, close monitoring of 
pulse and blood pressure is indicated early in treatment. Sleep disturbance, usually in the form of 
midsleep awakening, occurred in 6 of these 25 cases. This observation suggests that sleep history 
should be established at baseline and monitored during treatment. The management of sleep 
disturbance appears to be somewhat individualized, but shifting the time of the last dose or the 
distribution of doses was a successful strategy in some cases. 
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